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Aims: Cognitive decline in Alzheimer's disease (AD) is highly related to synaptic/neuronal loss. Tau 
hyperphosphorylation destabilizes microtubules leading to axonal transport failure and generation of 
dystrophic neurites, thus contributing to synaptic dysfunction. The effect of microtubule stabilization on 
amyloid-  of the 
microtubule-stabilizing agent, Epothilone D (EpoD) in the pathology of an amyloidogenic mouse model. 
Methods: APP751SL/PS1M146L mice (3-month-old) were treated weekly with intraperitoneal injections of 
EpoD (2 mg/kg) or vehicle for 3 months. For memory performance, animals were tested on the object-
recognition, Y-maze and Morris water maze. Hippocampal proteinopathies were quantified by image 
analysis after immunostaining. Somatostatin (SOM)-numerical density was calculated by stereology. 
APPswe-N2a cells were treated with EpoD 100nM for 12/24 hours. Protein levels were analysed by 
Western/dot-blot. 
Results: EpoD-treated mice improved their performance of cognitive tests, while hippocampal phospho-
Remarkably, EpoD exerted a neuroprotective effect on SOM-interneurons, a highly AD-vulnerable 
GABAergic subpopulation. 
Conclusions: EpoD improved microtubule dynamics and axonal transport in an AD-like context, reducing 
between cytoskeleton pathology and proteinopathy. Therefore, microtubule-stabilizing drugs could be 
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